The trial’s Phase I dose-escalation stage is being carried out across various sites in the US. Credit: National Cancer Institute on Unsplash.

Sapience Therapeutics has dosed the first patient in the ST316-101 Phase I-II trial of its ST316 antagonist of β-catenin for the treatment of advanced solid tumours.

The first-in-human, open-label, dose-escalation and expansion trial aims to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), and early efficacy of ST316.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Its Phase I dose-escalation stage will examine multiple dose levels of ST316 in patients with select advanced solid tumours that usually harbour the Wnt/β-catenin signalling pathway abnormalities.

This portion, which is being carried out across various sites in the US, is anticipated to be completed in the second half of next year.

Upon completion of this portion, Sapience will advance the recommended dose to the Phase II portion of the trial.

See Also:

In Phase II, ST316 will be investigated in four advanced solid tumour types.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ST316 can selectively target the Wnt/β-catenin signalling pathway’s oncogenic activation, without affecting its activity in normal cells.

Sapience Therapeutics chief medical officer Dr Abi Vainstein-Haras said: “Dosing our first patient with ST316 is a significant accomplishment for our team, which has remained undaunted by the challenge of drugging one of the most challenging cancer targets, the Wnt/β-catenin pathway.

“We are thrilled to advance our second molecule from the bench to the clinic. Given the relevance of Wnt/β-catenin in the development of multiple cancers, we are excited about ST316’s potential to make a meaningful difference for the many patients suffering from cancers driven by abnormalities in this pathway.”

This March, Sapience secured IND approval from the US Food and Drug Administration (FDA) to commence a Phase I-II trial of ST316 to treat solid tumours.